Healthcare stocks
Peer comparison of the 7 Healthcare stocks tracked by R40, ordered by market cap.
Ordered by market cap, largest first — not by Rule of 40 score.
| Company | R40 | Market cap | Price | Revenue growth | FCF margin | P/E |
|---|---|---|---|---|---|---|
LLY
Eli Lilly and Company
|
R40812026 Q2 | $1.04T | $1,152.44 | +47.7% | +33.8% | 40.2 |
JNJ
Johnson & Johnson
|
R40352026 Q2 | $656.26B | $270.22 | +6.6% | +28.8% | 29.4 |
ABBV
AbbVie Inc.
|
R40282026 Q2 | $467.58B | $264.02 | +10.2% | +18.3% | 71.1 |
UNH
UnitedHealth Group Incorporated
|
R40102026 Q2 | $339.94B | $375.21 | +0.4% | +9.2% | 26.8 |
MRNA
Moderna, Inc.
|
R40n/m2026 Q2 | $62.91B | $158.07 | +2.1% | −388.3% | n/m |
HIMS
Hims & Hers Health, Inc.
|
R40302026 Q2 | $6.35B | $27.89 | +38.2% | −8.2% | n/m |
ABCL
AbCellera Biologics Inc.
|
R40n/m2026 Q2 | $3.89B | $12.73 | −76.3% | +587.4% | n/m |
Latest Healthcare news
News
· UNH
UnitedHealth Guided Revenue Down 2% and It Went Up 1%. The Gap Is Worth 40 Cents of a $2.00 EPS Raise.
UnitedHealth's January floor was $439.0B, a guided 2% decline. First-half revenue rose 1.2% to $223.8B, and the over-run is worth $0.40 of a $2.00 EPS raise.
R40
News
· JNJ
J&J Won the First-Ever wAIHA Approval on Nine Responders in 38. The Effect's Lower Bound Is 0.1 Points.
J&J's Imaavy is the first drug ever approved for wAIHA: nine of 38 responded against three of 39 on placebo, a 16-point gap whose 95% interval starts at 0.1.
R40
News
· HIMS
A $75,000 Visa Fee Caps Hims's July Card Charges at 625,000. Hims Has 2.9 Million Subscribers.
Hims is billed about $75,000 at $8 a dispute. Visa's 1.5% threshold caps that at 625,000 Visa charges in July, against 2.891 million subscribers.
R40